Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aviva Biosciences Corp.

This article was originally published in Start Up

Executive Summary

Aviva Biosciences recently commercialized its first product, a micro-fabricated electrophysiology chip for high-throughput screening of compounds that affect ion channels-potentially one of the most attractive sources of drug targets. The company is also developing a chip-based system for enriching rare cells in fluids and separating them out, including fetal cells from maternal blood, cancer cells, and stem cells.

You may also be interested in...



The Re-Emergence of Ion Channel Drug Discovery

Historically ion channels have been among the most attractive targets for therapeutic intervention. But discovery of new ion channel drugs has come to a halt because ion channels are difficult to assay, require specialized tools and skills to study adequately, and have historically been impossible to study directly in high-throughput mode-the preferred style of the last decade. Now, a variety of automated assay technologies are coming on the market that should increase throughput, and some drug discovery companies have developed proprietary high-throughput methods for in-house use. With industry now interested more than ever in applying higher-throughput technologies to precedented targets, in a sense, ion channel discovery may become a beneficiary of the failures of genomics, combinatorial chemistry, and high-throughput screening.

Oncology Market Trends: Predictive Biomarkers, New IO Targets And Tougher Competition

Higher success rates in rare cancers, where biomarkers can better direct therapy, characterize the oncology treatment landscape. Deal-making is favoring alliances over acquisitions as drugmakers focus on establishing the clinical benefit of new targets, particularly for rare indications.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel